ZyVersa Non Currrent Assets Other from 2010 to 2024
| ZVSA Stock | 2.16 0.04 1.82% |
Non Currrent Assets Other | First Reported 2010-12-31 | Previous Quarter 98.5 K | Current Value 148 K | Quarterly Volatility 88.7 K |
Check ZyVersa Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ZyVersa Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 K, Interest Expense of 444.5 K or Selling General Administrative of 11.8 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0832. ZyVersa financial statements analysis is a perfect complement when working with ZyVersa Therapeutics Valuation or Volatility modules.
ZyVersa | Non Currrent Assets Other |
Latest ZyVersa Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of ZyVersa Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. ZyVersa Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ZyVersa Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
ZyVersa Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 264,759 | |
| Geometric Mean | 238,746 | |
| Coefficient Of Variation | 33.51 | |
| Mean Deviation | 66,816 | |
| Median | 308,324 | |
| Standard Deviation | 88,722 | |
| Sample Variance | 7.9B | |
| Range | 261.7K | |
| R-Value | (0.68) | |
| Mean Square Error | 4.6B | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (13,486) | |
| Total Sum of Squares | 110.2B |
ZyVersa Non Currrent Assets Other History
About ZyVersa Therapeutics Financial Statements
ZyVersa Therapeutics stakeholders use historical fundamental indicators, such as ZyVersa Therapeutics' Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although ZyVersa Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ZyVersa Therapeutics' assets and liabilities are reflected in the revenues and expenses on ZyVersa Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ZyVersa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 98.5 K | 148 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in ZyVersa Stock
When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out the analysis of ZyVersa Therapeutics Correlation against competitors. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.2 K | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.